<DOC>
	<DOCNO>NCT02710643</DOCNO>
	<brief_summary>Phase II prospective multicenter study stage I/II Follicular Lymphoma treat involved-field radiotherapy ( IFRT ) dose 24 Gy ) without Ofatumumab 8 weekly dos molecular basis . Patients positive basal Bcl-2 follow every 3 month Bcl-2 detection every 6 month 3 year . Patient negative basal Bcl-2 follow every 3 month without Bcl-2 detection . Ofatumumab treatment administer : 1 . Patients positive basal PCR Bcl-2-IgH rearrangement BM and/or PB , result still positive IFRT ; 2 . Patients positive basal PCR Bcl-2-IgH</brief_summary>
	<brief_title>`` MIRO '' Molecularly Oriented Immuno-radio-therapy</brief_title>
	<detailed_description>Stage I/IIA follicular lymphoma ( FL ) consider localized disease adequately treat radiotherapy alone . This strategy recommend guideline `` Società Italiana di Ematologia '' ( SIE ) `` European Society Medical Oncology '' ( ESMO ) The accurate definition truly localise form represent crucial issue order ensure appropriate treatment design patient . The characteristic ( 14 ; 18 ) translocation , lead over-expression Bcl-2 gene , find approximately 85 % FL ; cell bear translocation detect peripheral blood ( PB ) bone marrow ( BM ) polymerase chain reaction ( PCR ) . PCR ( 14 ; 18 ) translocation provide sensitive device identify presence minimal non-Hodgkin lymphoma ( NHL ) cell contamination . Previous experience demonstrate despite limited stage , Bcl-2/IgH+ cell find diagnosis PB and/or BM majority patient . After treatment local radiotherapy confine involved lymph node ( ) , disappearance circulate Bcl-2/IgH+ cell PB and/or BM demonstrate approximately 60 % positive patient . Quantitative PCR demonstrate feasibility clearing PB BM Bcl-2+ cell local irradiation primary site disease basal number lymphoma cell &lt; 1:100 000 . Anti-CD20 monoclonal antibody treatment clearly demonstrate , alone combination chemotherapy radiotherapy , high therapeutic potential FL . A significant impact treatment anti CD20 monoclonal antibody reduce minimal residual disease FL demonstrate several study use consolidation maintenance phase . No data currently available concern ability anti-CD20 antibody treatment reduce proportion Bcl-2 positive residual cell radiotherapy localize FL . The objective study take advantage therapeutic potential anti-CD20 monoclonal antibody reduce eliminate minimal residual disease patient FL localize stage ( I/II ) conventional treatment local radiotherapy involve site ( ) . The effectiveness anti-CD20 monoclonal antibody treatment determine proportion negativization residual Bcl-2 positive cell radiotherapy , evaluate qualitative quantitative PCR detection viable Bcl-2/IgH rearrange cell PB and/or BM .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm follicular lymphoma grade IIIIa ; Stage IA IIA ( 2 contiguous nodal region ) non bulky ( &lt; 7 cm ) ; FLIPI &lt; 2 , FLIPI2 &lt; 2 ; Previously untreated ; Age ≥ 18 ; Informed consent ; Staging PETCT , bone marrow biopsy ; Qualitative/quantitative PCR basal evaluation Bcl2/IgH rearrange cell peripheral blood bone marrow . Follicular lymphoma grade IIIb ; Stage great II 2 nodal site and/or B symptom and/or bulky disease ( &gt; 7 cm ) ; FLIPI &gt; 2 , FLIPI2 &gt; 2 ; Age &lt; 18 ; Previous treatment nonHodgkin 's lymphoma ; Dementia ; Impossibility subscribe inform consent ; Subjects current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone stable chronic liver disease per investigator assessment ) ; Treatment know nonmarketed drug substance experimental therapy within 5 terminal half live 4 week prior enrollment , whichever longer , currently participate interventional clinical study ; Other past current malignancy . Subjects free malignancy least 5 year , history completely resect nonmelanoma skin cancer , successfully treat situ carcinoma eligible ; Chronic current infectious disease require systemic antibiotic , antifungal , antiviral treatment , limited , chronic renal infection , chronic chest infection bronchiectasis , tuberculosis active Hepatitis C ; History significant cerebrovascular disease past 6 month ongoing event active symptom sequelae ; Known HIV positive ; Clinically significant cardiac disease include unstable angina , acute myocardial infarction within six month prior start treatment , congestive heart failure ( NYHA IIIIV ) , arrhythmia unless controlled therapy , exception extra systole minor conduction abnormality ; Significant concurrent , uncontrolled medical condition include , limited , renal , hepatic , gastrointestinal , endocrine , pulmonary , neurological , cerebral psychiatric disease opinion investigator may represent risk patient ; Positive serology Hepatitis B ( HB ) define positive test HBsAg . In addition , negative HBsAg HBcAb positive ( regardless HBsAb status ) , quantitative HBVDNA test perform positive subject exclude . Patients HBcAb positivity negative HBV DNA prophilactically treat oral Lamivudine ( 100 mg /day ) case treatment Ofatumumab , prosecute 12 month treatment ; Positive serology hepatitis C ( HC ) define positive test HCAb , case reflexively perform HCVRNA sample confirm result ; Hematologic blood chemistry exclusion criterion : platelet &lt; 50 x 109/L ; neutrophil &lt; 1.0 x 109/L ; creatinine &gt; 2.0 time upper normal limit ; total bilirubin &gt; 1.5 time upper normal limit ; ALT &gt; 2.5 time upper normal limit ; alkaline phosphatase &gt; 2.5 time upper normal limit ; Pregnant lactate woman . Women childbearing potential must negative pregnancy test screening : Women childbearing potential , include woman whose last menstrual period less one year prior screening , unable unwilling use adequate contraception study start one year last dose protocol therapy . Adequate contraception define hormonal birth control , intrauterine device , double barrier method total abstinence ; Male subject unable unwilling use adequate contraception method study start one year last dose protocol therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Follicular</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Grade 1</keyword>
	<keyword>Grade 2</keyword>
</DOC>